Iridex Secures European Patent for MicroPulse Technology

Iridex, a pioneering company in the field of medical devices, announced the grant of the European Patent 'EP 3009093.' This patent, titled "Laser System with Short Pulse Characteristics and its Methods of Use," signifies a significant milestone for the company, protecting its intellectual property in the realm of laser systems used in ophthalmology and related fields.

The patented technology, which forms the core of Iridex's MicroPulse devices, represents a breakthrough in enhancing the safety and effectiveness of laser treatments. By delivering short, controlled-width pulse trains, the technology aims to mitigate the risk of full-thickness retinal damage and vision loss, thereby revolutionizing laser-based interventions in retina and glaucoma applications.

Numerous clinical studies have underscored the safety and efficacy of this innovative approach, showcasing its potential to redefine standards of care in ophthalmic procedures. The key to its success lies in its ability to leverage a diode pump source and a frequency-doubled solid-state visible laser, resulting in a pulsed output with precisely controlled thermal effects. This enables tissue-specific photoactivation without causing detrimental photocoagulation damage, a significant advancement in the field.

David Bruce, President and CEO of Iridex Corporation, expressed his enthusiasm about the patent grant, emphasizing its implications for advancing patient care. "This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology, and the patent grant affirms our exclusive position as the only authorized provider of MicroPulse technology," Bruce stated in a news release.